415 related articles for article (PubMed ID: 28677745)
21. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
23. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control.
Cochand-Priollet B; Dahan H; Laloi-Michelin M; Polivka M; Saada M; Herman P; Guillausseau PJ; Hamzi L; Poté N; Sarfati E; Wassef M; Combe H; Raulic-Raimond D; Chedin P; Medeau V; Casanova D; Kania R
Thyroid; 2011 Oct; 21(10):1067-73. PubMed ID: 21875347
[TBL] [Abstract][Full Text] [Related]
24. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
25. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
26. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J
Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
Kim MJ; Kim HJ; Hong SJ; Shong YK; Gong G
Acta Cytol; 2006; 50(1):28-34. PubMed ID: 16514837
[TBL] [Abstract][Full Text] [Related]
29. Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19.
Zehani A; Bani A; Chelly I; Rejaibi S; Besbes G; Haouet S; Kchir N
Tunis Med; 2018 Feb; 96(2):113-121. PubMed ID: 30324976
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
31. Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration.
Jung CK; Lee A; Jung ES; Choi YJ; Jung SL; Lee KY
Acta Cytol; 2008; 52(3):313-9. PubMed ID: 18540296
[TBL] [Abstract][Full Text] [Related]
32. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications.
Rorive S; Eddafali B; Fernandez S; Decaestecker C; André S; Kaltner H; Kuwabara I; Liu FT; Gabius HJ; Kiss R; Salmon I
Mod Pathol; 2002 Dec; 15(12):1294-301. PubMed ID: 12481010
[TBL] [Abstract][Full Text] [Related]
33. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
35. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens.
Giannini R; Faviana P; Cavinato T; Elisei R; Pacini F; Berti P; Fontanini G; Ugolini C; Camacci T; De Ieso K; Miccoli P; Pinchera A; Basolo F
Thyroid; 2003 Aug; 13(8):765-70. PubMed ID: 14558920
[TBL] [Abstract][Full Text] [Related]
37. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression.
Salajegheh A; Dolan-Evans E; Sullivan E; Irani S; Rahman MA; Vosgha H; Gopalan V; Smith RA; Lam AK
Exp Mol Pathol; 2014 Apr; 96(2):212-8. PubMed ID: 24530443
[TBL] [Abstract][Full Text] [Related]
38. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
39. Runt-Related Transcription Factor 2 (Runx2) Is Responsible for Galectin-3 Overexpression in Human Thyroid Carcinoma.
Kaptan E; Sancar Bas S; Sancakli A; Aktas HG; Bayrak BB; Yanardag R; Bolkent S
J Cell Biochem; 2017 Nov; 118(11):3911-3919. PubMed ID: 28390192
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
Xu XC; el-Naggar AK; Lotan R
Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
